Xenograft tumor models were established to assess the impact of TIM-3 expression on the tumorigenic potential of AML cells with and without the RUNX1-RUNX1T1 fusion (Figure 3E). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.